BiotechTube

LP-300 + Pemetrexed + Carboplatin

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma of Lung

Conditions

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Trial Timeline

Mar 1, 2023 → Jun 1, 2026

NCT ID
NCT05456256

About LP-300 + Pemetrexed + Carboplatin

LP-300 + Pemetrexed + Carboplatin is a phase 2 stage product being developed by Lantern Pharma for Adenocarcinoma of Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05456256. Target conditions include Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05456256Phase 2Recruiting

Competing Products

20 competing products in Adenocarcinoma of Lung

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
44
RamucirumabEli LillyPhase 1/2
41
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
77
BA3182BioAtlaPhase 1
25
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
33
CT-P16 + AvastinCelltrionPhase 3
77
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
77
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41
EnzalutamideAstellas PharmaPhase 2
52
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23

Other Products from Lantern Pharma

Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel + Placebo in combination with cisplatin and docetaxel or paclitaxelPhase 3
69
BNP7787 + PlaceboPhase 3
69
IrofulvenPhase 2
44
LP-184 + Spironolactone + OlaparibPhase 1/2
33
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug)Phase 1/2
33